Brown, J R
Hillmen, P
O’Brien, S
Barrientos, J C
Reddy, N M
Coutre, S E
Tam, C S
Mulligan, S P
Jaeger, U
Barr, P M
Furman, R R
Kipps, T J
Cymbalista, F
Thornton, P
Caligaris-Cappio, F
Delgado, J http://orcid.org/0000-0002-5157-4376
Montillo, M
DeVos, S
Moreno, C
Pagel, J M
Munir, T
Burger, J A
Chung, D
Lin, J
Gau, L
Chang, B
Cole, G
Hsu, E
James, D F
Byrd, J C
Article History
Received: 17 February 2017
Revised: 11 May 2017
Accepted: 23 May 2017
First Online: 8 June 2017
Competing interests
: JRB has received honoraria from Celgene, Gilead, Infinity, Genentech/Roche, Janssen, Pharmacyclics, Pfizer and Sub BioPharma, has served in an advisory role for Celgene, Gilead, Infinity, Genentech, Janssen, Pfizer and Pharmacyclics, and has been reimbursed for expenses by Gilead, Sun BioPharma, Pfizer and Janssen. PH has served as a consultant for Roche, Glaxo Smith Kline, Janssen, Gilead, and AbbVie, received honoraria from AbbVie, Gilead, Glaxo Smith Kline, Roche, Novartis, Pharmacyclics and Janssen, and research funding from Roche, Novartis, Glaxo Smith Kline, Janssen, Gilead, AbbVie, Celgene, Pharmacyclics. SOB has served as a consultant and received honoraria from Pharmacyclics and Janssen, and received research funding from Pharmacyclics. JCBarrientos has served as a consultant to Gilead, AbbVie, and Janssen, and received research funding from AbbVie and Gilead. NMR has served as a consultant for Celgene, Infinity, Gilead, and AbbVie. SEC has served in an advisory role for Janssen and Pharmacyclics, and has received research funding from AbbVie and Pharmacyclics. CT has received honoraria from Janssen, research funding from Janssen, and has served in an advisory role for Janssen. SPM has served as a consultant for and received honoraria from AbbVie, Gilead, Glaxo Smith Kline, Janssen, Roche, received research funding from AbbVie, Janssen, Roche, participated in speakers’ bureau for AbbVie, Gilead, Janssen, Roche. UJ has served as a consultant, and received honoraria and reimbursements from Janssen and Roche. PMB has served as a consultant for Pharmacyclics, AbbVie and received research funding from Pharmacyclics. RRF has received honoraria from Pharmacyclics, and has served in an advisory role and on Speakers’ Bureaus for Pharmacyclics. TJK has served as a consultant for AbbVie, Genentech, Gilead, and received research funding from AbbVie, Genentech, Pharmacyclics. FC has received research funding from Janssen, honoraria from Gilead, Janssen, Mundipharma and AbbVie, has consulted for Gilead, Janssen and AbbVie, and been reimbursed by Janssen, and Roche. PT has served as a consultant for Janssen. FCC has received honoraria and served as a consultant for Celgene, Janssen, Pharmacyclics. JD has received honoraria from and served as a consultant for Gilead, Novartis, Glaxo Smith Kline, Janssen, Roche, and received research funding from Infinity, Roche. MM has received honoraria from and served in a consultancy role for Roche, Gilead, and Janssen, and received honoraria from Novartis. SDV and CM have no relevant conflicts of interest to disclose. JMP has served as a consultant for Gilead and Pharmacyclics, and received research funding from Pharmacyclics, AbbVie, and TG Therapeutics. TM has received honoraria from Pharmacyclics, Gilead, and Alexion and has served as a consultant for Morphosys. JAB has served as a consultant for Janssen, Portola, has received research funding from Gilead, Pharmacyclics, and reimbursement from Janssen, Roche. DC is employed by Pharmacyclics and has stock/ownership in Gilead and AbbVie. JL, LG, BC, GC, EH, DFJ are employed by Pharmacyclics and have stock/ownership in AbbVie. JCByrd has no relevant conflict of interest to disclose.